SCHEMBL3584067

SCHEMBL3584067

Nc1cccc2c1S(=O)(=O)CC(=O)N2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLCG1 P19174 1/20 0.54
CA2 P00918 2/20 0.38
AHR P35869 1/20 0.35
PDK2 Q15119 1/20 0.35
NPC1 O15118 1/20 0.34
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34
MAPK14 Q16539 1/20 0.34
CA9 Q16790 2/20 0.34
BRD4 O60885 4/20 0.33
CREBBP Q92793 4/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 2/20 0.33
CCNB2 O95067 1/20 0.31
CDK1 P06493 1/20 0.31
CCNB1 P14635 1/20 0.31
GSK3B P49841 1/20 0.31
CDK5 Q00535 1/20 0.31
CDK5R1 Q15078 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3584066 0.79 PLCG1 (0.54) PLCG1CA2AHRPDK2NPC1
SCHEMBL3594526 0.72 PLCG1 (0.54) PLCG1CA2AHRCA9ALDH1A1
SCHEMBL88748 0.71 PLCG1 (1.00) PLCG1CA2AHRPDK2NPC1
SCHEMBL836954 0.67 AHR (0.48) AHRPDK2CCNB2CDK1CCNB1
SCHEMBL3600873 0.67 PLCG1 (0.61) PLCG1CA2AHRCA9MAPT
SCHEMBL3598842 0.67 PLCG1 (0.61) PLCG1CA2AHRCA9MAPT
SCHEMBL3212830 0.66 NPC1 (0.50) AHRPDK2NPC1MAPK13MAPK12
SCHEMBL3584556 0.64 CREBBP (0.38) PLCG1AHRPDK2NPC1MAPK13
SCHEMBL10422612 0.63 PLCG1 (0.47) PLCG1CA2CA9ALDH1A1MAPT
SCHEMBL254031 0.63 SMYD3 (0.48) AHRPDK2BRD4CREBBPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 PLCG1 4081/4885CA2 887/4885AHR 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.